Roche CT-388 Obesity Drug Posts 22.5% Weight Loss

Roche CT-388 Obesity Drug shows up to 22.5% placebo-adjusted weight loss at 48 weeks, as Roche moves into Phase 3 to challenge Lilly and Novo.

Membership Required

You must be a member to access this content.

View Membership Levels

Already a member? Log in here

Tagged Biopharma Pipeline, Carmot Therapeutics, CT-388, diabetes, GIP, GLP-1, Metabolic Disease, mounjaro, Obesity Drugs, Phase 2 Trial, Phase 3 Trial, Roche, Tirzepatide, Weight Loss Market, Zepbound